soul trial oral semaglutide cardiovascular outcomes nejm 2025 results 🚨 25 mg delivers double-digit weight loss in OASIS-4 (Phase 3 trial) - New in the May 29,

They aren't one-to-one comparisons

GLP-1 drugs were developed to treat diabetes and obesity, not for cosmetic weight loss in healthy, normal-weight individuals, and understanding that gap is the key to using these medicines safely

Therefore, these findings further support the observation that low IGF-1 preferentially benefits females, and suggest that a potentially broad therapeutic window to target IGF-1R signaling may exist in females, with greater benefit possible by initiating at even younger ages than implemented in this study

Additionally, mice consuming M-HFHSD during both active and rest phases exhibited enhanced glucose tolerance